Integrated Analysis of Tumor Differentiation Genes in Pancreatic Adenocarcinoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Mar 30

PMID 29596435

Citations 9

Authors

Ting Xi

Guizhi Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Tumor differentiation is an important process in the development of cancer. It is valuable to identify key differentiation related genes in the prognosis and therapy of pancreatic adenocarcinoma.

Methods: The mRNA expression data were downloaded from the Cancer Genome Atlas database. Then, differentially expressed tumor differentiation related genes were identified. Additionally, Gene Ontology functional categories and Kyoto Encyclopedia of Genes and Genomes biochemical pathway was used to explore the function. In addition, receiver operating characteristic and survival analysis were carried out to assess the diagnosis and prognosis value. Finally, the electronic validation of selected tumor differentiation related genes was performed.

Results: A total of 932 genes were identified. Among which, 8 genes including JUB, ERLIN1, HMGA2, FAM110B, EGFR, MCM2, TCTA and SSTR1 were differentially expressed in all different tumor differentiation grades. Functional analysis revealed those genes between highly differentiated and other differentiation were remarkably enriched in pancreatic adenocarcinoma and cell cycle pathway. Finally, ERLIN1, HMGA2, FAM110B, EGFR, MCM2, BCL2L1, E2F1 and RAC1 were associated with the survival time of pancreatic adenocarcinoma patient. Among these genes, JUB, ERLIN1, FAM110B, MCM2 and BCL2L1 also had a diagnosis value for pancreatic adenocarcinoma. Additionally, the expression trend of JUB, HMGA2 and MCM2 was increased along with the tumor differentiation grades. And the expression trend of FAM110B was decreased along with the tumor differentiation grades. The electronic validation result was consistent with the bioinformatics analysis.

Conclusions: 12 tumor differentiation related genes including JUB, ERLIN1, HMGA2, FAM110B, EGFR, MCM2, TCTA, SSTR1, BCL2L1, E2F1, RAC1 and STAT1 played crucial roles in the differentiation of pancreatic adenocarcinoma.

Citing Articles

Pan-cancer analysis and single-cell analysis reveals FAM110B as a potential target for survival and immunotherapy.

Li Y, Li X, Wu B, Su S, Su Y, Guo L Front Mol Biosci. 2024; 11:1424104.

PMID: 39170745 PMC: 11335499. DOI: 10.3389/fmolb.2024.1424104.

Adjuvant Chemotherapy With or Without Radiotherapy for Resected Pancreatic Cancer After Multiagent Neoadjuvant Chemotherapy.

Franklin O, Sugawara T, Ross R, Franco S, Colborn K, Karam S Ann Surg Oncol. 2024; 31(8):4966-4975.

PMID: 38789615 DOI: 10.1245/s10434-024-15157-4.

FAM family gene prediction model reveals heterogeneity, stemness and immune microenvironment of UCEC.

Chi H, Gao X, Xia Z, Yu W, Yin X, Pan Y Front Mol Biosci. 2023; 10:1200335.

PMID: 37275958 PMC: 10235772. DOI: 10.3389/fmolb.2023.1200335.

Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.

Cao K, Ling X, Jiang X, Ma J, Zhu J Respir Res. 2022; 23(1):306.

PMID: 36357897 PMC: 9650835. DOI: 10.1186/s12931-022-02226-z.

Matrine impedes colorectal cancer proliferation and migration by downregulating endoplasmic reticulum lipid raft associated protein 1 expression.

Ren H, Wang Y, Guo Y, Wang M, Ma X, Li W Bioengineered. 2022; 13(4):9780-9791.

PMID: 35412433 PMC: 9161898. DOI: 10.1080/21655979.2022.2060777.

References

Yamanaka Y, Friess H, Kobrin M, Buchler M, Beger H, Korc M . Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993; 13(3):565-9. View

Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E . Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene. 2000; 19(48):5477-86. DOI: 10.1038/sj.onc.1203936. View

Hejna M, Schmidinger M, Raderer M . The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?. Ann Oncol. 2002; 13(5):653-68. DOI: 10.1093/annonc/mdf142. View

Matsubayashi H, Sato N, Fukushima N, Yeo C, Walter K, Brune K . Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res. 2003; 9(4):1446-52. View

Yin Z, Liu J, Xu Y, Yu J, Ding G, Yang F . A 41-gene signature derived from breast cancer stem cells as a predictor of survival. J Exp Clin Cancer Res. 2014; 33:49. PMC: 4229870. DOI: 10.1186/1756-9966-33-49. View

Ochs C, Perl Y, Halper M, Geller J, Lomax J . Quality assurance of the gene ontology using abstraction networks. J Bioinform Comput Biol. 2016; 14(3):1642001. DOI: 10.1142/S0219720016420014. View

Browman D, Resek M, Zajchowski L, Robbins S . Erlin-1 and erlin-2 are novel members of the prohibitin family of proteins that define lipid-raft-like domains of the ER. J Cell Sci. 2006; 119(Pt 15):3149-60. DOI: 10.1242/jcs.03060. View

Olson M, Ashworth A, Hall A . An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995; 269(5228):1270-2. DOI: 10.1126/science.7652575. View

Lei M, Tye B . Initiating DNA synthesis: from recruiting to activating the MCM complex. J Cell Sci. 2001; 114(Pt 8):1447-54. DOI: 10.1242/jcs.114.8.1447. View

10.

Nakamura T, Fidler I, Coombes K . Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment. Cancer Res. 2007; 67(1):139-48. DOI: 10.1158/0008-5472.CAN-06-2563. View

11.

Sarkar F, Li Y, Wang Z, Kong D . Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009; 64(5):489-500. PMC: 2878773. View

12.

Pan J, Yang M . The role of epithelial-mesenchymal transition in pancreatic cancer. J Gastrointest Oncol. 2012; 2(3):151-6. PMC: 3397615. DOI: 10.3978/j.issn.2078-6891.2011.022. View

13.

Long J, Liu Z, Wu X, Xu Y, Ge C . Screening for genes and subnetworks associated with pancreatic cancer based on the gene expression profile. Mol Med Rep. 2016; 13(5):3779-86. PMC: 4838159. DOI: 10.3892/mmr.2016.5007. View

14.

Hauge H, Patzke S, Aasheim H . Characterization of the FAM110 gene family. Genomics. 2007; 90(1):14-27. DOI: 10.1016/j.ygeno.2007.03.002. View

15.

Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R . Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2012; 493(7432):406-10. PMC: 3759028. DOI: 10.1038/nature11725. View

16.

Adams J, Cory S . The Bcl-2 protein family: arbiters of cell survival. Science. 1998; 281(5381):1322-6. DOI: 10.1126/science.281.5381.1322. View

17.

Johnson D . The paradox of E2F1: oncogene and tumor suppressor gene. Mol Carcinog. 2000; 27(3):151-7. DOI: 10.1002/(sici)1098-2744(200003)27:3<151::aid-mc1>3.0.co;2-c. View

18.

Weichert W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhaus P . Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology. 2005; 5(2-3):259-65. DOI: 10.1159/000085280. View

19.

Walczak H, Bouchon A, Stahl H, Krammer P . Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res. 2000; 60(11):3051-7. View

20.

Satoh K, Shimosegawa T, Hirota M, Koizumi M, Toyota T . Expression of transforming growth factor beta1 (TGFbeta1) and its receptors in pancreatic duct cell carcinoma and in chronic pancreatitis. Pancreas. 1998; 16(4):468-74. DOI: 10.1097/00006676-199805000-00002. View